The role of molecular imaging in the characterization of renal masses
Authors:
- 1 March 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 28 (2) , 159-165
Abstract
To explore the role of molecular imaging in the characterization of renal masses. Incidentally detected renal masses exhibit variable malignant potential related to their underlying histology. Patients presenting with a renal mass should undergo individual risk stratification including characterization of their tumor histology. At the present time, anatomical imaging techniques are unable to reliably distinguish between the various renal tumor subtypes. Although renal mass biopsy is helpful in this regard, there are limitations of this procedure. Molecular imaging offers a noninvasive means of determining the histology of renal tumors. Imaging tests that have shown particular promise for this application include I-girentuximab PET/CT for diagnosing clear cell renal cell carcinoma and Tc-sestamibi SPECT/CT for diagnosing renal oncocytomas and hybrid oncocytic/chromophobe tumors. Molecular imaging offers a noninvasive means of determining the histology of renal tumors thereby aiding in the risk stratification of patients presenting with a renal mass. Future work aims to develop a molecular imaging test that employs dual radiotracers allowing for the more precise characterization of renal tumors in a convenient single radiologic study.Keywords
This publication has 55 references indexed in Scilit:
- Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot studyAbdominal Radiology, 2015
- Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CTAnnals of Nuclear Medicine, 2015
- PET/CT imaging in cancer: Current applications and future directionsCancer, 2014
- Biodistribution and Radiation Dosimetry of the Carbonic Anhydrase IX Imaging Agent [18 F]VM4-037 Determined from PET/CT Scans in Healthy VolunteersMolecular Imaging and Biology, 2014
- Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinomaAnnals of Nuclear Medicine, 2010
- Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal CarcinomaMolecular Imaging and Biology, 2009
- 11C-Acetate PET imaging for renal cell carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Renal cell cancer stage migrationCancer, 2008
- Rising Incidence of Renal Cell Cancer in the United StatesJAMA, 1999